Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 154Lymphoma 78Lymphoma, Non-Hodgkin 62Neoplasms, Plasma Cell 54Leukemia 52Leukemia, Myeloid, Acute 49Hodgkin Disease 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Leukemia, Lymphocytic, Chronic, B-Cell 45Myelodysplastic Syndromes 42Lymphoma, Large B-Cell, Diffuse 41Lymphoma, Follicular 40Lymphoma, Mantle-Cell 38Lymphoma, Large-Cell, Immunoblastic 29Neuroblastoma 27Burkitt Lymphoma 27Lymphoma, B-Cell, Marginal Zone 26Recurrence 22Immunoglobulin Light-chain Amyloidosis 22Myeloproliferative Disorders 18Leukemia, Myeloid, Accelerated Phase 16Hematologic Neoplasms 16Congenital Abnormalities 16Leukemia, Myeloid, Chronic-Phase 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Graft vs Host Disease 14Dendritic Cell Sarcoma, Interdigitating 14Waldenstrom Macroglobulinemia 13Leukemia, Myelomonocytic, Chronic 13Blast Crisis 13

Interventions

Radiotherapy 6Fibroblast Growth Factor 7 4Injections 3Drug Therapy 3Cisplatin 3Water 2Propolis 2Mouthwashes 2Morphine 2Methotrexate 2Melphalan 2Low-Level Light Therapy 2Interleukin 1 Receptor Antagonist Protein 2Gabapentin 2Cryotherapy 2peppermint oil 1pegaspargase 1oxycodone-acetaminophen 1nelarabine 1kang-lai-te 1glucarpidase 1fludarabine phosphate 1fish oil triglycerides 1cyclohexaneacetic acid 1calcium phosphate 1brilacidin 1anise oil 1amlexanox 1aluminum hydroxide, magnesium hydroxide, drug combination 1acetaminophen, hydrocodone drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Mucositis × Melphalan × Clear all
NCT01085617 2025-03-30

UKALL14

University College, London

Completed
OtherOther hematologic neoplasm

Leukemia, Mucositis

NCT00482846 2014-04-15

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
38 enrolled
OtherPlasma cell

Multiple Myeloma, Mucositis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡